Get the Stockscreener App
14.30
2.12%
-0.31
Pre-market:
14.69
0.39
+2.73%
Anika Therapeutics Inc stock is traded at $14.30, with a volume of 59,832.
It is down -2.12% in the last 24 hours and down -4.09% over the past month.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
See More
Previous Close:
$14.61
Open:
$14.69
24h Volume:
59,832
Relative Volume:
0.57
Market Cap:
$190.27M
Revenue:
$116.26M
Net Income/Loss:
$-11.08M
P/E Ratio:
-18.06
EPS:
-0.7917
Net Cash Flow:
$1.04M
1W Performance:
-1.85%
1M Performance:
-4.09%
6M Performance:
+50.37%
1Y Performance:
+28.71%
1-Day Range:
$14.28
$14.69
1-Week Range:
$14.25
$15.14
52-Week Range:
$7.8701
$16.24
Anika Therapeutics Inc Stock (ANIK) Company Profile
Name
Anika Therapeutics Inc
Sector
Phone
(781) 457-9000
Address
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
14.30 | 194.40M | 116.26M | -11.08M | 1.04M | -0.7917 |
TAK
Takeda Pharmaceutical Co Adr
|
15.66 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.09 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.33 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.27 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | B. Riley Securities | Buy |
| Nov-01-24 | Reiterated | Barrington Research | Outperform |
| Aug-14-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Mar-07-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-09-22 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-14-22 | Resumed | Stephens | Equal-Weight |
| Mar-09-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-09-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-16-21 | Initiated | Stephens | Overweight |
| Jul-16-21 | Initiated | UBS | Neutral |
| Dec-16-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-21-20 | Upgrade | Sidoti | Neutral → Buy |
| Jan-10-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Nov-05-19 | Initiated | BWS Financial | Sell |
| Sep-24-19 | Reiterated | Barrington Research | Outperform |
| Sep-23-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Strong Buy |
| Feb-22-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Feb-22-19 | Downgrade | Sidoti | Buy → Neutral |
| Jul-27-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jun-20-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-20-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| May-04-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-23-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-24-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Oct-27-17 | Reiterated | Barrington Research | Outperform |
| May-09-16 | Upgrade | Singular Research | BUY - Long-Term → Buy |
| Apr-27-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-26-16 | Reiterated | Barrington Research | Outperform |
View All
Anika Therapeutics Inc Stock (ANIK) Latest News
(ANIK) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Anika Therapeutics (ANIK) Holds Steady Near Support Amid Low VolumeMonthly Profile - newsline.com
Anika Therapeutics Q1 2026 Earnings: Massive EPS Beat Fuels OptimismConsensus Forecast Report - newsline.com
Anika reports inducement grants - Medical Buyer
Anika Therapeutics grants 3,360 RSUs to new employee as inducement under Nasdaq rules. - Pluang
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Anika hire receives 3,360 stock units as job inducement - Stock Titan
Anika (NASDAQ: ANIK) CEO exercises RSUs, withholds shares to cover tax - Stock Titan
Anika Therapeutics introduces proprietary Hyaff material for next generation regenerative applications - Traders Union
How (ANIK) Movements Inform Risk Allocation Models - Stock Traders Daily
Anika Therapeutics (ANIK) Holds Steady Near Support as Slight Decline PersistsIV Contraction - thelegaladvocate.com
Anika Therapeutics (ANIK) Hovers Near Support With Minimal Price MovementResistance Breakout Stocks - newsline.com
Anika Therapeutics (ANIK) Slides 1.6% Amidst Market Pressure – Key Levels to WatchOrder Block - The Legal Advocate
ANIK Stock Analysis: Anika Therapeutics Inc. gains 3.31 percent daily, trades at 14.98 dollar - Newser
ORIC Stock Heads Into Weekend as Cancer-Trial Deadline Approaches - Bez Kabli
Trading Systems Reacting to (ANIK) Volatility - Stock Traders Daily
Anika Therapeutics (ANIK) Q1 2026 Earnings: Surprise EPS Beat Amid Revenue UncertaintyAnnual Financial Report - newsline.com
ANIK Q1 2026 Earnings: Surprise Profit Swing as Anika Therapeutics Beats ExpectationsAnnual Earnings Summary - Newser
Why Is Anika Therapeutics, Inc. (ANIK) Stock Up Today? - Meyka
Anika Therapeutics Signals Momentum Amid Regulatory Risks - The Globe and Mail
Anika Therapeutics honors Clinical Trials Day as it advances patient outcomes - Traders Union
Anika maintains 2026 revenue guidance of $114M-$122.5M while highlighting Integrity growth and Hyalofast FDA response work - MSN
Why Is Anika Therapeutics, Inc. (ANIK) Stock Down Today? - Meyka
Anika Therapeutics invites ESSKA Congress delegates to explore advances in HA-based cartilage repair - Traders Union
About Us | Oil & Gas JournalAnika Therapeutics Inc.Common Stock (Nasdaq:ANIK) Stock Quote - FinancialContent
TradingKey - TradingKey
How Anika Therapeutics Inc. (ANIK) Affects Rotational Strategy Timing - Stock Traders Daily
Anika Therapeutics (ANIK) Eps Diluted (TTM) - Zacks Investment Research
How Anika (ANIK) margins compare to industry leaders (+0.13%) 2026-05-08High Attention Stocks - newser.com
ANIK (Anika) Q1 earnings crush estimates by 265%, but shares barely budge amid revenue softness.Earnings Forecast Report - newsline.com
Anika Therapeutics explores why skin heals rapidly but tendons and cartilage lag in recovery - Traders Union
Number of shareholders of Anika Therapeutics Inc. – NASDAQ:ANIK - TradingView
Insider Buying: HENNEMAN JOHN B III Acquires 5,000 Shares of Ani - GuruFocus
Anika Therapeutics Q1 2026 earnings preview - MSN
Anika Therapeutics director John Henneman buys $73,319 in shares By Investing.com - Investing.com Canada
Anika Therapeutics director John Henneman buys $73,319 in shares - Investing.com
Anika Therapeutics (ANIK) director adds 5,000 shares in open-market buy - Stock Titan
President of Anika Therapeutics Picks Up 51% More Stock - Yahoo Finance
Anika Therapeutics (NASDAQ:ANIK) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat
Anika Therapeutics Q1 2026 Financial Results: Revenue, Losses, and Key Financial Statements Overview - minichart.com.sg
ANIK | Anika Therapeutics Inc Insider Trading - Quiver Quantitative
Anika Therapeutics Projects $114 Million Revenue Growth for Fiscal 2026 - HarianBasis.co
Insider Buying: Stephen Griffin Acquires Shares of Anika Therape - GuruFocus
Anika Therapeutics (NASDAQ:ANIK) CEO Purchases $149,938.00 in Stock - MarketBeat
Anika Therapeutics Inc Stock (ANIK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anika Therapeutics Inc Stock (ANIK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Griffin Stephen D. | President and CEO |
Apr 30 '26 |
Buy |
12.29 |
12,200 |
149,881 |
36,163 |
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):